Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
CEMPRA, INC. (MLNT)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 06/24/2020 |
GN
| Melinta Therapeutics Announces Termination of Merger Agreement and Tender Offer for Shares of Tetraphase |
| 06/09/2020 |
GN
| Melinta Therapeutics Enters Into Agreement to Acquire Tetraphase Pharmaceuticals |
| 03/04/2020 |
GN
| Melinta Therapeutics Confirms Deerfield as Successful Bidder for Company |
| 02/13/2020 |
GN
| Melinta Therapeutics Announces Court Approval of Chapter 11 Bidding Procedures |
| 12/27/2019 |
GN
| Melinta Therapeutics Announces Restructuring Support Agreement with its Secured Lenders under its Senior Credit Facility |
| 11/12/2019 |
GN
| Melinta Therapeutics Files Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2019 |
| 08/06/2019 |
GN
| Melinta Therapeutics Announces Rescheduling of Second Quarter 2019 Financial Results Reporting |
| 07/16/2019 |
GN
| Melinta Therapeutics Announces Preliminary Second Quarter 2019 Financial Results and Provides Corporate Update |
| 06/19/2019 |
GN
| Melinta Therapeutics Announces U.S. FDA Acceptance of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia |
| 05/09/2019 |
GN
| Melinta Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update |
| 05/07/2019 |
GN
| Melinta Therapeutics to Present at Making a Difference in Infectious Diseases (MAD-ID) 2019 Annual Meeting |
| 04/19/2019 |
GN
| New Research: Key Drivers of Growth for Conatus Pharmaceuticals, MasTec, Cyclacel Pharmaceuticals, Melinta Therapeutics, North American Construction Group, and B.O.S. Better Online Solutions — Factors of Influence, Major Initiatives and Sustained Production |
| 02/25/2019 |
GN
| Melinta Therapeutics Announces Closing of Initial $75 Million Vatera Convertible Loan Funding |
| 02/21/2019 |
GN
| Melinta Therapeutics Announces One-for-Five Reverse Stock Split |
| 02/04/2019 |
GN
| Melinta Therapeutics Provides Corporate Updates |
| 12/19/2018 |
GN
| John H. Johnson Agrees to Become Permanent Chief Executive Officer of Melinta Therapeutics |
| 11/30/2018 |
GN
| INVESTIGATION NOTICE: Kaskela Law LLC Announces Investigation of Melinta Therapeutics, Inc. on Behalf of Stockholders – MLNT |
| 11/27/2018 |
GN
| Melinta Therapeutics Granted European Commission Marketing Authorization for Vabomere® (meropenem and vaborbactam) |
| 11/16/2018 |
GN
| New Research: Key Drivers of Growth for Fresh Del Monte Produce, Liquidity Services, B.O.S. Better Online Solutions, ePlus inc, Pluralsight, and Melinta Therapeutics — Factors of Influence, Major Initiatives and Sustained Production |
| 10/31/2018 |
GN
| UPDATE - Melinta Therapeutics Announces Appointment of Bruce L. Downey to Board of Directors |
| 10/26/2018 |
GN
| Melinta Therapeutics to Report Third Quarter 2018 Financial Results on November 7, 2018 |
| 10/05/2018 |
GN
| Melinta Therapeutics Publishes Findings from Orbactiv® (oritavancin) Real-World Registry Demonstrating Efficacy and Safety Consistent with Phase 3 SOLO Program |
| 10/01/2018 |
GN
| Melinta Therapeutics and Menarini Group Enter Commercial Agreement for Vabomere™ (meropenem and vaborbactam), Orbactiv® (oritavancin) and Minocin® (minocycline) for Injection in 68 Countries |
| 09/24/2018 |
GN
| Melinta Therapeutics to Give New Presentations on Antibiotics Portfolio and Pipeline at IDWeek™ 2018 |
| 09/21/2018 |
GN
| Melinta Therapeutics Receives Positive CHMP Opinion for Vabomere™ (meropenem and vaborbactam) |
| 08/29/2018 |
GN
| Melinta Therapeutics to Present at the Rodman & Renshaw 20th Annual Global Investment Conference |
| 08/07/2018 |
GN
| Melinta Therapeutics Reports Second Quarter 2018 Financial Results |
| 08/03/2018 |
GN
| Melinta Therapeutics Announces Vabomere™ (meropenem and vaborbactam) Granted New Technology Add-On Payment by CMS |
| 07/11/2018 |
GN
| Melinta Therapeutics to Report Second Quarter 2018 Financial Results on August 7, 2018 |
| 05/29/2018 |
GN
| Melinta Therapeutics Announces Closing of Underwritten Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional Shares of Common Stock |
| 05/23/2018 |
GN
| Melinta Therapeutics Announces Pricing of Public Offering of Common Stock |
| 05/21/2018 |
GN
| Melinta Therapeutics Announces Proposed Offering of Common Stock |
| 05/11/2018 |
GN
| Melinta Therapeutics Launches New Antibiotic Stewardship Program to Combat Growing Threat of Antimicrobial Resistance |
| 04/27/2018 |
GN
| Melinta Therapeutics to Report First Quarter 2018 Financial Results on May 8, 2018 |
|
|
|